Company news
Hcw Biologics Inc. (NASDAQ:HCWB) news
Every Hcw Biologics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
August 17, 2026
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
July 29, 2026
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical T...
July 23, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
June 30, 2026
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
June 26, 2026
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immun...
June 16, 2026
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 27, 2026
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
May 22, 2026
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 21, 2026
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 14, 2026
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
April 30, 2026
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target...
April 27, 2026
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
March 31, 2026
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
March 17, 2026
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound...
March 16, 2026
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
March 2, 2026
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
February 17, 2026
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
February 13, 2026
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
November 19, 2025
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
November 18, 2025
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
November 14, 2025
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the So...
November 10, 2025
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th An...
November 7, 2025
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
October 22, 2025
HCW Biologics to Participate in the 2025 Maxim Growth Summit
October 16, 2025
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
October 16, 2025
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
September 30, 2025
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
September 18, 2025
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic ...
September 16, 2025
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
September 9, 2025
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Do...
August 25, 2025
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
August 18, 2025
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers A...
June 27, 2025
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
June 26, 2025
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
June 4, 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
May 15, 2025
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
May 13, 2025
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
May 13, 2025
HCW Biologics Announces 1-for-40 Reverse Stock Split
April 1, 2025
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
March 28, 2025
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
March 6, 2025
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
February 3, 2025
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan...
January 15, 2025
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
December 23, 2024
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
November 18, 2024
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NAS...
November 18, 2024
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
November 14, 2024
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
August 23, 2024
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
August 14, 2024
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
May 15, 2024